Here’s what you should know.
1. Mr. Icahn held nearly $700 million in Allergan shares at the end of June 2016. By the end of September 2016, he decreased his holdings to $98 million.
2. Mr. Icahn said he was supportive of the efforts of CEO Brent Saunders, but announced he had no plans to be an activist for the company.
3. Allergan has purchased several small pharmaceutical companies in the recent months. The company failed to close a merger with New York-based Pfizer in April 2016.
More articles on healthcare:
Healthcare predictive analytics market to surge to $19.5B by 2025 — 6 things to know
Celeste Carole to manage Finger Lakes Surgery Center: 3 notes
30 things that happened in November for ASC leaders to know
